Ágnes Benedict - Concepedia

Author

Ágnes Benedict

United BioSource Corporation (United Kingdom)ORCID

Also Known As

A Benedict, A. Benedict, Adole Ekedegwa Benedict, Agnes Benedict, Ameya Elizabeth Benedict, Benedict Á, H James, L Fallowfield, Pierce, À Benedict

111

Publications

1.6K

Citations

H-Index

Concepts

All Affiliations

United BioSource Corporation (United Kingdom)Research Triangle Park Foundation University of Sheffield Harvard University The University of Texas Southwestern Medical Center

ÁB

About

Ágnes Benedict is an author at United BioSource Corporation (United Kingdom) specializing in medicine, oncology, and outcomes research.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	10	10	359
2	Health Sciences	3	3	56
3	Public Health	3	3	174
4	Social Sciences	1	1	27
5	Biostatistics	1	1	17

Ágnes Benedict

Publications

712

Citations

H-Index

Page 1

	Year	Citations
Simulation and Matching-Based Approaches for Indirect Comparison of Treatments K. Jack Ishak, Irina Proskorovsky, Ágnes Benedict PharmacoEconomics Comparative Effectiveness ResearchMatching-based ApproachesMatching TechniqueMedicineTreatment Effect	2015	103
INCIDENCE-BASED COST-OF-ILLNESS MODEL FOR METASTATIC BREAST CANCER IN THE UNITED STATES Sonja Sorensen, Jo Wern Goh, Feng Pan, International Journal of Technology Assessment in Health Care	2012	71
Treatment costs of prostate cancer in the first year after diagnosis: a short‐term cost of illness study for France, Germany, Italy, Spain and the UK R. Fourcade, Ágnes Benedict, Libby Black, British Journal of Urology	2009	68
Cost-effectiveness of adding carfilzomib to lenalidomide and dexamethasone in relapsed multiple myeloma from a US perspective Andrzej Jakubowiak, Marco Campioni, Ágnes Benedict, Journal of Medical Economics	2016	51
Economic evaluation of new targeted therapies for the first‐line treatment of patients with metastatic renal cell carcinoma Ágnes Benedict, Robert A. Figlin, Per Sandström, British Journal of Urology	2011	45
Prevalence of Immature Survival Data for Anti-Cancer Drugs Presented to the National Institute for Health and Care Excellence and Impact on Decision Making T.A. Tai, Nicholas Latimer, Ágnes Benedict, Value in Health Immature Survival DataCare ExcellenceOncologyNational InstituteCancer Management	2020	42
First-year costs of treating prostate cancer: estimates from SEER-Medicare data Claus G. Roehrborn, Peter C. Albertsen, Michael E. Stokes, Prostate Cancer and Prostatic Diseases UrologySurgical OncologyHealthcare ValueHealth EconomicsHealth Policy	2009	37
QL4 PATIENT-RATED UTILITIES IN POSTMENOPAUSAL EARLY BREAST CANCER (EBC):A CROSS-COUNTRY COMPARISON SV Sorensen, Rebecca M. Brown, Ágnes Benedict, Value in Health Breast OncologyOncologyCancer ManagementOutcomes ResearchPatient-reported Outcome	2004	36
Long-term medical-care costs related to prostate cancer: estimates from linked SEER-Medicare data Michael E. Stokes, Libby Black, Ágnes Benedict, Prostate Cancer and Prostatic Diseases UrologyHealthcare ValueSeer-medicare DataHealth PolicyHealth Economics	2010	34
Clinical and Economic Outcomes Associated with Treatment Sequences In Patients With <i>BRAF</i> -Mutant Advanced Melanoma Ahmad A. Tarhini, David F. McDermott, Apoorva Ambavane, Immunotherapy	2018	34

Page 1